XOMA ROYALTY is a biotechnology royalty aggregator. The company acquires the potential future economics associated with pre-commercial therapeutic candidates which have been licensed to pharmaceutical or biotechnology companies. XOMA ROYALTY, formerly known as XOMA Corporation, is based in EMERYVILLE, Calif.
| Revenue (Most Recent Fiscal Year) | $28.49M |
| Net Income (Most Recent Fiscal Year) | $-13.82M |
| PE Ratio (Current Year Earnings Estimate) | 37.16 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 8.80 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 5.41 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -34.07% |
| Net Margin (Trailing 12 Months) | -27.57% |
| Return on Equity (Trailing 12 Months) | 2.63% |
| Return on Assets (Trailing 12 Months) | 0.97% |
| Current Ratio (Most Recent Fiscal Quarter) | 4.88 |
| Quick Ratio (Most Recent Fiscal Quarter) | 4.88 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 1.41 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $5.99 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.48 |
| Earnings per Share (Most Recent Fiscal Year) | $-3.99 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.55 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 12.09M |
| Free Float | 10.99M |
| Market Capitalization | $395.27M |
| Average Volume (Last 20 Days) | 0.06M |
| Beta (Past 60 Months) | 1.00 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 9.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 95.92% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |